Patents Assigned to Ottawa Hospital Research Institute
-
Publication number: 20240132913Abstract: The disclosure relates to modified orthopoxvirus vectors, as well as methods of using the same for the treatment of various cancers. The disclosure provides modified orthopoxvirus vectors that exhibit various beneficial therapeutic activities, including enhanced oncolytic activity, spread of infection, immune evasion, tumor persistence, capacity for incorporation of exogenous DNA sequences and safety. The viruses we have discovered are also amenable to large scale manufacturing protocols.Type: ApplicationFiled: September 4, 2023Publication date: April 25, 2024Applicants: OTTAWA HOSPITAL RESEARCH INSTITUTE, TURNSTONE BIOLOGICS CORP.Inventors: John C. Bell, Fabrice Le Boeuf, Michael S. Huh, Matthew Y. Tang, Adrian Pelin, Brian Andrew Keller, Caroline J. Breitbach, Michael F. Burgess, Steven H. Bernstein
-
Patent number: 11802292Abstract: The disclosure relates to modified orthopoxvirus vectors, as well as methods of using the same for the treatment of various cancers. The disclosure provides modified orthopoxvirus vectors that exhibit various beneficial therapeutic activities, including enhanced oncolytic activity, spread of infection, immune evasion, tumor persistence, capacity for incorporation of exogenous DNA sequences and safety. The viruses we have discovered are also amenable to large scale manufacturing protocols.Type: GrantFiled: January 4, 2019Date of Patent: October 31, 2023Assignees: OTTAWA HOSPITAL RESEARCH INSTITUTE, TURNSTONE BIOLOGICS CORP.Inventors: John C. Bell, Fabrice Le Boeuf, Michael S. Huh, Matthew Y. Tang, Adrian Pelin, Brian Andrew Keller, Caroline J. Breitbach, Michael F. Burgess, Steven H. Bernstein
-
Patent number: 11739350Abstract: The present disclosure provides a miRNA hairpin that, when processed by a virus-infected cell, increases the therapeutic effectiveness of the virus. The present disclosure also provides a virus encoding such a miRNA hairpin. The present disclosure also provides pre-miRNAs that, when processed by a virus-infected cell, increase extracellular vesicle secretion of the encoded miRNA hairpin by the virus-infected cell.Type: GrantFiled: April 10, 2019Date of Patent: August 29, 2023Assignee: OTTAWA HOSPITAL RESEARCH INSTITUTEInventors: Carolina Solange Ilkow, John Cameron Bell, Victoria Ann Maher, Briana Livia Rollande Samson
-
Publication number: 20230114123Abstract: The present disclosure provides a method for stimulating asymmetric division of at least some satellite stem cells in a patient suffering from a disease or disorder characterized by satellite cells having an inability, or a reduced ability, to assemble a functional dystrophin-associated glycoprotein complex (DGC) that results in an inability, or reduced ability, to establish cell polarity. The method includes administering to the patient a sufficient amount of an epidermal growth factor receptor (EGFR) pathway activator to stimulate asymmetric division of at least some satellite stem cells.Type: ApplicationFiled: October 6, 2022Publication date: April 13, 2023Applicant: Ottawa Hospital Research InstituteInventors: Michael A. Rudnicki, Yu Xin Wang
-
Publication number: 20230022757Abstract: The disclosure relates to modified vaccinia virus vectors derived from the Copenhagen strain of vaccinia virus, as well as methods of using the same for the treatment of various cancers. The disclosure provides modified Copenhagen-derived vaccinia virus vectors that exhibit various beneficial therapeutic activities, including enhanced oncolytic activity, spread of infection, immune evasion, tumor persistence, capacity for incorporation of exogenous DNA sequences, amenability for large scale manufacturing, and safety.Type: ApplicationFiled: March 14, 2022Publication date: January 26, 2023Applicant: OTTAWA HOSPITAL RESEARCH INSTITUTEInventors: John C. Bell, Fabrice Le Boeuf, Michael S. Huh, Matthew Y. Tang, Brian Andrew Keller, Adrian Pelin
-
Patent number: 11517598Abstract: Provided herein are methods for enhancing infection, growth, spread, or titer of an oncolytic RNA virus in a cancer or tumor cell; enhancing the oncolytic activity, cytokine-induced cell death activity, and/or cytotoxic activity of an oncolytic RNA virus in a cancer or tumor cell; upregulating cytokine response to, and/or enhancing the immunotherapeutic activity of an oncolytic RNA virus in a cancer or tumor cell; and/or treating a tumor or cancer in a subject in need thereof. Such methods employ a vanadium-containing compound, administered to the cancer or tumor cells before, after, or concurrently with infection of the cancer or tumor cells with the oncolytic RNA virus. Related compositions, uses, and kits therefor are also provided. Methods for producing RNA viruses, RNA virus-based cancer vaccines, and RNA virus-based cancer gene therapy vectors are also provided.Type: GrantFiled: October 3, 2017Date of Patent: December 6, 2022Assignee: Ottawa Hospital Research InstituteInventors: Mohammed Selman, Jean-Simon Diallo
-
Publication number: 20220380799Abstract: The disclosure relates to modified orthopoxvirus vectors, as well as methods of using the same for the treatment of various cancers. The disclosure provides modified orthopoxvirus vectors that exhibit various beneficial therapeutic activities, including enhanced oncolytic activity, spread of infection, immune evasion, tumor persistence, capacity for incorporation of exogenous DNA sequences, amenability for large scale manufacturing, and safety.Type: ApplicationFiled: December 20, 2019Publication date: December 1, 2022Applicants: OTTAWA HOSPITAL RESEARCH INSTITUTE, TURNSTONE BIOLOGICS CORP.Inventors: John C. BELL, Michael S. HUH, Matthew Y. TANG, Adrian PELIN, Caroline J. BREITBACH, Michael F. BURGESS, Steven H. BERNSTEIN
-
Publication number: 20220220101Abstract: Provided are compounds that enhance the efficacy of viruses by increasing spread of the virus in cells, increasing the titer of virus in cells, or increasing the antigen expression from a virus, gene or trans-gene expression from a virus, or virus protein expression in cells. Other uses, compositions and methods of using same are also provided.Type: ApplicationFiled: March 31, 2022Publication date: July 14, 2022Applicants: Ottawa Hospital Research Institute, University of OttawaInventors: Jean-Simon Diallo, Christopher Noyce Boddy, Mark Dornan, Ramya Krishnan, Rozanne Arulanandam, Fabrice Le Boeuf, Jeffrey Smith, Andrew Macklin
-
Patent number: 11339448Abstract: Herein are described methods of treating a human subject having acute myeloid leukemia (AML) that is refractory to induction therapy, wherein an MDM2 inhibitor is administered before or concurrently with chemotherapy, which may comprise induction therapy. Refractory AML may be predicted based on decreased expression of MTF2 in cells from a hematological sample obtained from the subject. Also provided are methods of predicting and treating AML responsive to MDM2/HDM2 inhibitors, based on MTF2 expression. One set of additional biomarkers useful in the predictions comprise one or more of H3K27me3, CD84, CD92, MDM2, NPM1, PRICKLE1, SET, ABCB6, POLQ, POLK, POLH, ARTIMIS, MCM6, CD327, CD90 and PARP1. Another set of additional biomarkers useful in the predictions include at least one of H3K27me3, MDM2, NPM1, SET, CD84 and PRICKLE1. Methods of selecting a patient for treatment with an MDM2 inhibitor before or concurrently with chemotherapy are also provided, along with kits and uses.Type: GrantFiled: July 26, 2019Date of Patent: May 24, 2022Assignee: Ottawa Hospital Research InstituteInventors: William Stanford, Caryn Ito, Mitchell Sabloff, Harinad Babu Maganti, Hani Jrade, Harold Atkins
-
Patent number: 11339146Abstract: Provided are compounds of Formula (II) that enhance the efficacy of viruses by increasing spread of the virus in cells, increasing the titer of virus in cells, or increasing the antigen expression from a virus, gene or trans-gene expression from a virus, or virus protein expression in cells. Other uses, compositions and methods of using same are also provided.Type: GrantFiled: May 18, 2020Date of Patent: May 24, 2022Assignee: Ottawa Hospital Research Institute and University of OttawaInventors: Jean-Simon Diallo, Christopher Noyce Boddy, Mark Dornan, Ramya Krishnan, Rozanne Arulanandam, Fabrice Le Boeuf, Jeffrey Smith, Andrew Macklin
-
Publication number: 20220056480Abstract: The disclosure relates to modified orthopoxvirus vectors, as well as methods of using the same for the treatment of various cancers. The disclosure provides modified orthopoxvirus vectors that exhibit various beneficial therapeutic activities, including enhanced oncolytic activity, spread of infection, immune evasion, tumor persistence, capacity for incorporation of exogenous DNA sequences, amenability for large scale manufacturing, and safety.Type: ApplicationFiled: December 20, 2019Publication date: February 24, 2022Applicants: OTTAWA HOSPITAL RESEARCH INSTITUTE, TURNSTONE BIOLOGICS CORP.Inventors: John C. BELL, Michael S. HUH, Matthew Y. TANG, Adrian PELIN, Caroline J. BREITBACH, Michael F. BURGESS, Steven H. BERNSTEIN
-
Publication number: 20210233330Abstract: There is provided a system and method for applying markings to a three-dimensional virtual image or virtual object, the system comprising a physical stylus, a surface, and a virtual or augmented reality display. A virtual space is displayed by the virtual or augmented reality display. The virtual space includes a three-dimensional target object; at least one plane, including a tracking plane, the tracking plane corresponding to the surface; and a virtual stylus in a virtual reality view, or the physical stylus in an augmented reality view. A position of the virtual stylus or the physical stylus relative to the tracking plane is correlated to an actual position of the physical stylus relative to the surface; and a cross-section of the target object is displayed on the tracking plane where the tracking plane intersects the target object.Type: ApplicationFiled: July 8, 2019Publication date: July 29, 2021Applicant: Ottawa Hospital Research InstituteInventors: Justin SUTHERLAND, Daniel LA RUSSA
-
Publication number: 20200392535Abstract: The disclosure relates to modified orthopoxvirus vectors, as well as methods of using the same for the treatment of various cancers. The disclosure provides modified orthopoxvirus vectors that exhibit various beneficial therapeutic activities, including enhanced oncolytic activity, spread of infection, immune evasion, tumor persistence, capacity for incorporation of exogenous DNA sequences and safety. The viruses we have discovered are also amenable to large scale manufacturing protocols.Type: ApplicationFiled: January 4, 2019Publication date: December 17, 2020Applicants: OTTAWA HOSPITAL RESEARCH INSTITUTE, TURNSTONE BIOLOGICS CORP.Inventors: John C. BELL, Fabrice LE BOEUF, Michael S. HUH, Matthew Y. TANG, Adrian PELIN, Brian Andrew KELLER, Caroline J. BREITBACH, Michael F. BURGESS, Steven H. BERNSTEIN
-
Publication number: 20200385758Abstract: The disclosure relates to modified vaccinia virus vectors derived from the Copenhagen strain of vaccinia virus, as well as methods of using the same for the treatment of various cancers. The disclosure provides modified Copenhagen-derived vaccinia virus vectors that exhibit various beneficial therapeutic activities, including enhanced oncolytic activity, spread of infection, immune evasion, tumor persistence, capacity for incorporation of exogenous DNA sequences, amenability for large scale manufacturing, and safety.Type: ApplicationFiled: January 4, 2019Publication date: December 10, 2020Applicant: OTTAWA HOSPITAL RESEARCH INSTITUTEInventors: John C. BELL, Fabrice LE BOEUF, Michael S. HUH, Matthew Y. TANG, Brian Andrew KELLER, Adrian PELIN
-
Publication number: 20200354351Abstract: Provided are compounds that enhance the efficacy of viruses by increasing spread of the virus in cells, increasing the titer of virus in cells, or increasing the antigen expression from a virus, gene or trans-gene expression from a virus, or virus protein expression in cells. Other uses, compositions and methods of using same are also provided.Type: ApplicationFiled: May 18, 2020Publication date: November 12, 2020Applicants: Ottawa Hospital Research Institute, University of OttawaInventors: Jean-Simon Diallo, Christopher Noyce Boddy, Mark Dornan, Ramya Krishnan, Rozanne Arulanandam, Fabrice Le Boeuf, Jeffrey Smith, Andrew Macklin
-
Patent number: 10828346Abstract: There are provided compositions and methods for modulating stem cell division decisions, in particular, division symmetry. It has been demonstrated that wnt7a acts through frizzled-7 receptor expressed on the surface of adult stem cells, e.g. satellite stem cells, to activate the planar cell polarity (PCP) pathway, thereby promoting symmetrical expansion of stem cells. The compositions and methods of the invention are useful, for example, in modulating stem cell division symmetry in vitro and in vivo, in replenishing and expanding the stem cell pool, and in promoting the formation, maintenance, repair and regeneration of tissue.Type: GrantFiled: August 10, 2018Date of Patent: November 10, 2020Assignee: Ottawa Hospital Research InstituteInventors: Michael A. Rudnicki, Fabien Le Grand
-
Patent number: 10806802Abstract: A recombinant adeno-associated virus (rAAV) particle with a mutated capsid protein is provided. In particular, the present disclosure provides methods of delivering a therapeutic agent to a muscle, airway, liver, central nervous system, retina or lung cell in a subject, and methods of treating or preventing infectious, acquired or genetic disease, with said rAAV particle.Type: GrantFiled: January 18, 2019Date of Patent: October 20, 2020Assignees: University of Guelph, Ottawa Hospital Research InstituteInventors: Sarah Wootton, Laura van Lieshout, Bernard Claude Frank Thebaud, Martin Hubert Kang
-
Patent number: 10654839Abstract: Provided are compounds of Formula (II) that enhance the efficacy of viruses by increasing spread of the virus in cells, increasing the titer of virus in cells, or increasing the antigen expression from a virus, gene or trans-gene expression from a virus, or virus protein expression in cells. Other uses, compositions and methods of using same are also provided.Type: GrantFiled: January 26, 2016Date of Patent: May 19, 2020Assignees: Ottawa Hospital Research Institute, University of OttawaInventors: Jean-Simon Diallo, Christopher Noyce Boddy, Mark Dornan, Ramya Krishnan, Rozanne Arulanandam, Fabrice Le Boeuf, Jeffrey Smith, Andrew Macklin
-
Publication number: 20190231832Abstract: Provided herein are methods for enhancing infection, growth, spread, or titer of an oncolytic RNA virus in a cancer or tumor cell; enhancing the oncolytic activity, cytokine-induced cell death activity, and/or cytotoxic activity of an oncolytic RNA virus in a cancer or tumor cell; upregulating cytokine response to, and/or enhancing the immunotherapeutic activity of an oncolytic RNA virus in a cancer or tumor cell; and/or treating a tumor or cancer in a subject in need thereof. Such methods employ a vanadium-containing compound, administered to the cancer or tumor cells before, after, or concurrently with infection of the cancer or tumor cells with the oncolytic RNA virus. Related compositions, uses, and kits therefor are also provided. Methods for producing RNA viruses, RNA virus-based cancer vaccines, and RNA virus-based cancer gene therapy vectors are also provided.Type: ApplicationFiled: October 3, 2017Publication date: August 1, 2019Applicant: Ottawa Hospital Research InstituteInventors: Mohammed Selman, Jean-Simon Diallo
-
Patent number: 10172569Abstract: A system and method are provided that employ the variability of physiological waveforms to estimate the time to death after WLST, or time to inadequate organ perfusion. From the variability data one can derive an index subsequently used to determine the probability of death (or inadequate organ perfusion) within a given time frame in an automated fashion from bedside monitors in the intensive or post-anesthesia care unit. The resulting variability index can also be combined with the clinical variables used in other death prediction tools to enhance the performance and outcome when compared to existing models. In at least one implementation, variability monitoring at the bedside could be used to provide estimates of the probability that a patient will die within a certain time frame after WLST. These estimates could be used to reduce the distress of the patients' families, as well as optimize the use of resources surrounding donation.Type: GrantFiled: September 8, 2016Date of Patent: January 8, 2019Assignee: Ottawa Hospital Research InstituteInventors: Andrew J. E. Seely, Sonny Dhanani, Nathan B. Scales, Christophe L. Herry, Laura Hornby, Timothy O. Ramsay, Amanda S. Van Beinum